Results Then, anasarca and nephrosis was improved and S-Cr was decreased to 1.20 mg/dL in proportion to the reduction in activated Th17 cells in PD.

Conclusions Although recent studies have begun to shed light on the role of IL-17 in the pathogenesis of SLE, there is no convincing evidence in actual patients. In this case, improvement of disease activity of SLE was correlated with the decrease of activated Th17. This is the first report that the IL-17-targeted therapy for SLE was shown to be effective in a patient skewing towards Th17-phenotype.

DEVELOPMENT OF ARTEMISININ ANALOGUE ANALOG SM934 IN THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS

J Zuo, W Tang*. Shanghai Institute of Materia Medica- Chinese Academy of Sciences, Immunopharmacology, Shanghai, China

Background and aims Besides their outstanding antimalarial activity, artemisinin and its derivatives also possess immunosuppressive activities and are clinical used to treat SLE. β-aminooartheether maleate (SM934), a water soluble artemisinin derivative, got the approval documents authorised by Chinese FDA for clinical trials. This study investigated the curative effects of SM934 on lupus-prone mice and explored its underlying therapeutic mechanisms.

Methods In vivo, SM934 was given orally to female NZB/W F1 and MRL/lpr mice; renal injury, peripheral lymphoid organ disease and serological changes were evaluated. Meanwhile, correlative pathological mechanisms were studied using different aged mice. Besides, the effects of SM934 on human PBMCs were also assessed.

Results We demonstrated that SM934 treatment could significantly improve SLE syndrome in lupus-prone animal models, including delayed the progression of glomerulonephritis; ameliorated proteinuria and renal lesion severity; increased the survival rate; decreased levels of BUN and serum anti–double-stranded DNA antibodies. Furthermore, clinical improvement was accompanied with decreased Th1-related anti-dsDNA IgG2a and IgG3 Abs, serum IL-17, and increased Th2-related anti-dsDNA IgG1 Ab, serum IL-10 and IL-4. Moreover, SM934 could significantly inhibit both of Th1 and Th17 responses, elevate Treg percentage and lower the percentage of CD3+ B220+ CD4+ CD8- (double negative) T cells in MRL/lpr mice. We further elucidate that SM934 treatment restored the compartment of B cells in the spleen of MRL/lpr mice by increasing quiescent B cells, maintaining germinal centre B cells, decreasing activated B cells and reducing PCs.

Conclusions This work provides new evidence and clues for research about artemisinin compounds in the field of autoimmune diseases.

Other basic science

INCREASED NEUTROPHILS AND NEUTROPHIL SERINE PROTEASES IN THE SPLEENS OF ESTROGEN-TREATED C57BL/6 MICE AND IN SEVERAL STRAINS OF SPONTANEOUS LUPUS-PRONE MICE

Abstract 112 Figure 1 Estrogen treatment increases neutrophil number, NSP and MPO expression in wild type B6 mice. (A) Flow cytometry analysis of splenic neutrophil percentage in placebo- and estrogen-treated B6 mice. (B) The total splenocytes count in placebo- and estrogen-treated mice. (C) The total CD11b+GR1+ splenic neutrophil counts in placebo- and estrogen-treated mice. (D) and (E) Real-time RT-PCR analysis the expression of NSPs (D), and MPO (E) in splenocytes from placebo- and estrogen- treated mice. The graphs show means±SEMs (n≥4). Unpaired students t tests (placebo vs estrogen) were performed. *, p<0.05; **, p<0.01; and ***, p<0.001.
Abstract 112 Figure 2  Increased neutrophil percentages, NSPs, and MPO expression in the spleen cells of three different murine lupus strains. The graphs on left panel show the summary of flow analysis of neutrophil percentage in the spleens of MRL-<i>lpr</i> (A), B6-<i>lpr</i> (B), and NZBW<sub>F1</sub> (C). The graphs on right panel summarized the real-time RT-PCR analysis of the relative expression levels of NE, PR3, CG, and MPO in the splenocytes of

Abstract 112 Figure 3  Either depletion of NSPs in vivo or depletion splenic neutrophil in vitro has obvious effect on estrogen-mediated promotion of inflammatory molecules. (A-E): The splenocytes from placebo and estrogen-treated wild type (WT) and NSP<sup>-/-</sup> knock out mice were simulated with LPS to measure the production of IFNγ (A, LPS 6 hours), IL-6 (B, LPS 24 hours), MCP-1 (C, LPS 24 hours), and inflammatory molecule NO (D, LPS 48 hours). The expression iNOS protein levels in activated splenocytes (LPS placebo-and estrogen treated B6 mice were treated with anti-mouse Ly6G antibody to deplete neutrophils, and then simulated with LPS for 24 hours to measure IFNγ(F), IL-6 (G), and MCP-1 (H) production. The graphs show means±SEMs (n≥3). Unpaired student t tests (No Ab vs anti-Ly6G) were performed; *<i>p</i> < 0.05; **<i>p</i> < 0.01; and ***<i>p</i> < 0.001.
neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (CG) and myeloperoxidase (MPO) expression by qRT-PCR. NE+/PR3+/CG+/ triple knockout mice and in vitro depletion of neutrophils approaches were performed to determine the role of NSPs and neutrophils in estrogen-mediated inflammatory responses. The splenic neutrophil and NSPs expression in lupus-prone MRL-lpr, B6-lpr and NZB/WF1 mice and their respective controls were also analysed.

Results Although oestrogen reduced total splenocytes number, it markedly increased the splenic neutrophil numbers, NSPs and MPO expression in B6 mice (Figure 1). Splenic neutrophils, NSPs and MPO were also significantly increased in MRL-lpr, B6-lpr and NZB/WF1 mice (Figure 2). Despite of the critical role of NSPs and neutrophils in inflammation, depletion of NSPs in vivo did not affect oestrogen's ability to increase in splenic neutrophils nor the induction of inflammatory mediators from ex vivo activated splenocytes, and depletion of splenic neutrophils in vitro had also no obvious effect on NSPs expression (due to the increase of NSPs in cells other than neutrophils) and LPS-induced IFNγ and MCP-1 (Figure 3).

Conclusions Overall, we demonstrated a remarkable commonality with regards to the increase of neutrophils and NSPs in the spleens of autoimmune-prone mice and estrogen-treated B6 mice.

**Background and aims** Important miRNAs are involved in the modulation of immune functions and can be found in the intra- and extracellular environments, in circulation attached to RNA-binding molecules or packed in form of microparticles (MP). Given this, MP could have an important role in intercellular communication, modulation and expression of miRNAs in their target cells.

To establish whether MP of SLE patients can modulate the expression of miRNAs (miRNA 126, miRNA 146a) and their target molecule (interferon response factor 5, IRF5) in the monocyte cell line U937.

**Methods** MP obtained from serum of SLE and other autoimmune diseases (OAD) patients, and healthy controls were used as stimulus in the cell line U937 to evaluate their effect on: 1) The expression of membrane markers through flow cytometry, 2) content of miRNAs 126 and 146a through PCR and 3) expression of their target molecule, IRF5 by Western Blot.

**Results** We observed a decrease in HLA-DR, CD18, CD119 and an increase of IL-6 in U937 stimulated with MP from healthy controls, patients with active and inactive SLE, as well as patients with OAD. Additionally, a positive effect over the expression of miR126 and a negative effect over the expression of miR146a were observed. IRF5 as a target of miRNA146, did not change after MP treatment independent of MP origin.

**Conclusions** Our results suggested that MPs may have a regulatory effects, inducing a decreased expression of membrane molecules and miRNAs-146 levels, without effect in IRF5. In addition, MPs increased levels of cytokines and miRNA-126, latter is related with the demethylation.

**N-ACETYL-L-Cysteine (NAC) CONTROLS OSTEOCLASTOGENESIS THROUGH REGULATING TH17 DIFFERENTIATION AND RANKL PRODUCTION IN RHEUMATOID ARTHRITIS**

**Background and aims** This study aimed to determine the regulatory role of N-Acetyl-l-cysteine (NAC), an antioxidant, in IL-17-induced osteoclast differentiation in rheumatoid arthritis (RA).

**Methods** After RA synovial fibroblasts were stimulated by IL-17, the expression and production of RANKL was determined by real-time PCR and ELISA. Human peripheral blood monocytes were cultured with M-CSF, IL-17, RANKL, and/or various concentrations of NAC, followed by counting of the cells for tartrate-resistant acid phosphatase activity to determine osteoclast formation. Osteoclastogenesis was also determined after cocultures of IL-17-stimulated RA synovial fibroblasts, Th17 cells and various concentrations of NAC with monocytes. After human peripheral CD4+ T cells were cultured with NAC under Th17 condition, IL-17, IFN-g, IL-4, Foxp3, RANKL and IL-2 expression and production was determined by flow cytometry or ELISA.

**Results** When RA synovial fibroblasts were stimulated by IL-17, IL-17 stimulated the production of RANKL, and NAC reduced the IL-17-induced RANKL production in a dose-dependent manner. NAC decreased IL-17-activated phosphorylation of mTOR, JNK and IκB. When human peripheral blood CD14+ monocytes were cultured with M-CSF and IL-17 or RANKL, osteoclasts were differentiated, and NAC reduced the osteoclastogenesis. After human peripheral CD4+ T cells were co-cultured with IL-17-pretreated RA synovial fibroblasts or Th17 cells, NAC reduced their osteoclastogenesis. Under Th17 polarising condition, NAC decreased Th17 cell differentiation and IL-17 and RANKL production.

**Conclusions** NAC inhibits the IL-17-induced RANKL production in RA synovial fibroblasts and IL-17-induced osteoclast differentiation. NAC also reduced Th17 polarisation. NAC could be a supplementary therapeutic option for inflammatory and bony destructive processes in RA.